fashion -WSS

fashion

author：fashion 2025-10-02 18:48:04 - browse：43576

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： With fresh data, a dynamic duo powers Eli Lilly to new heights

WSS

Tennessee woman gets emergency hysterectomy after doctors deny early abortion care

Gain of function research would be limited under House proposal

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Weight loss drug costs may need more research, senator suggests

How corporate America is slashing DEI workers amid backlash to diversity programs

NYU radiologists take on the challenge of expensive MRI machines

focus

fashion

explore

Bright Health sells Medicare Advantage business to Molina

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Duchenne breakthrough therapy leaves behind pioneering families

The PBM ad wars are taking over Washington, D.C.

Tori Bowie and the unacceptable rates of Black maternal death

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Medicare details structure of new drug price negotiation program

How corporate America is slashing DEI workers amid backlash to diversity programs

Anesthesiologist group: stop taking Ozempic before surgery

Neutralizing antibodies against HIV shows promise in children

Wikipedia

A daunting task: navigating dual Medicare, Medicaid eligibility

Does good food count as health care? Study aims to find out

CRISPR pioneers react to Casgevy, first gene